Hot AI Mandate: Boston-based VC Invests in Pre-seed to Seed-stage AI/ML Companies

25 May

Founded in 2014, a venture capital is headquartered in Boston, MA. The firm focuses on pre-seed and seed-stage investments, typically with an initial investment of $500k to $1m as part of the company’s first institutional funding. The firm prefers companies located in the US and Canada. The firm will make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though they’re comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Hot AI Mandate: Hong Kong-based Boutique VC Interested in AI-related Healthcare Technologies

25 May

A boutique venture capital firm founded in 2015 in Hong Kong currently manages a 150M USD fund and a 200M RMB fund. The fund is industry agnostic within China while it focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Hot AI Mandate: CA-based Private Investment Group Interested in AI and Big Data Applications in Digital Health

25 May

A private/family investment vehicle based in CA makes seed investments via an accelerator arm, and also has a stage-agnostic fund. Seed investments are typically $25,000-100,000, and the firm is capable of making larger investments via the fund. The firm also provides a three-month accelerator program, and works with partners in the healthcare industry to strategically invest in startups. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology, and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables and health monitoring devices. Within digital health, interests include the following areas: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, Patient Adherence, Telemedicine. The firm s is interested in both consumer applications and enterprise software. The firm works with strategic

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise; for the accelerator program in particular, the firm prefers to work with companies that have a technical expert co-founder. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Join These Investor Panelists at Digital RESI June

20 May

By Joey Wong, Investor Research Analyst, LSN

Digital Redefining Early Stage Investment (RESI) Conference, June 8-10, takes place in just a few weeks! The Life Science Nation (LSN) investor research team has been busy organizing six exciting panels focusing on different investor groups, from big pharma, corporate venture capital, to family offices and angel investors, etc. During these panels, active life science investors will share their insight and provide tactical advice on outreach, positioning, and building the right relationships to move products forward. The goal is to facilitate constructive conversations between investors and fundraising CEOs, and provide insights on how companies can raise capital and acquire partnerships effectively.

Another exciting part of the upcoming conference is the Innovator’s Pitch Challenge, where investors and industry experts are invited to participate in the live Q&A sessions to give feedback and ask questions to the pitching companies.

If you are interested in meeting these investor panelists and pitch judges, register here for Digital RESI June! Partnering is open, but there is still time to sign up!

For those who have already registered, we highly recommend you to join the panels that are relevant to your company; you can RSVP for any panels in the partnering system to block off your meeting schedule.

Here are some of the investors who will be joining our panels and pitch sessions at Digital RESI June:

Hamzeh Abdul-Hadi
Principal
Hikma Ventures 		Brent Ahrens
General Partner
Canaan Partners 		Faz Bashi
Member of BOD
Life Science Angels 		Attila Bérces
Advisor
FastVentures
Brian Bronk
Head of External Innovation, Rare Diseases
Sanofi 		Hannah Chang
Managing Director
Wu Capital 		Elizabeth Cho-Fertikh
Co-Founder & Managing Director
Meda Angels 		Chris Church
Associate Director, Search & Evaluation, CVRM
AstraZeneca
Juan Cueva
Senior Associate
Action Potential Venture Capital 		Geoff Dacosta
Director, Business Development and Licensing
Medtronic 		Ben Evans
Managing Director
InHealth Ventures 		Naomi Fried
Managing Director & Co-Founder
Ambit Health Ventures
Robert Garber
Partner
7wire Ventures 		Miles Gerson
Partner
Takeda Ventures 		Sam Goldberger
Co-Founder & Managing Partner
Ambit Health Ventures 		Sherry Grisewood
Senior Investment Officer
FoxHill Asset Management
Bryan Grulke
Partner
Volcano Capital 		Eric Heinz
Director, Business Development (M&A)
Smith & Nephew 		Merom Klein
Entrepreneur Mentor
Keiretsu Forum 		Marc Martin-Casas
Seed Investments & Development
Illumina Accelerator
Andy Merken
Partner, Corporate and Securities Co-Chair, Life Sciences
Burns & Levinson 		Brian Meshkin
Managing Partner, Profound Ventures Partner, Cancer Fund
Profound Ventures 		Petra Meyer
Managing Director – HealthCare Sector Group Lead
Golden Seeds 		Junaid Mian
Managing Partner & Longevity Lead
SP8CEVC
Nicholas Mourlas
Senior Director, New Ventures
Johnson & Johnson Innovation 		Ashley Ng
Director
McKesson Ventures 		John Parker
Founder & Managing Director
Springhood Ventures 		Richard Proscia
Senior Associate
Providence Ventures
Meghana Rao
Senior Manager, New Venture Transactions
Johnson & Johnson Innovation 		Nadav Shimoni
Head, Digital Health
Arkin Holdings Ltd 		Yaniv Sneor
Founding Member
Mid Atlantic Bio Angels 		Jill Sorensen
Chief Operating Officer
Medical Technology Enterprise Consortium (MTEC)
Eran Steinberg

 

Imaging Arts

Ben Sun
Investor/member
Sand Hill Angels 		Anna Turetsky
Principal, Venture Investments
The Mark Foundation for Cancer Research (MFCR) 		Thomas Vogelsong
Investor/Life Science Advisor
KYTO Technology and Life Science
 
Scott Weiner
Partner
Amzak Health 		Tim Xiao
Principal
Delos Capital 		John Yianni
Managing Partner
Earlybird 		 

Introducing RESI AI Panels

20 May

By Caitlin Dolegowski, Marketing Specialist, LSN

Caiti

Life Science Nation has released panel topics for its upcoming digital partnering conference: RESI AI, September 16-17. RESI AI panels host active investors who are joined by founders of portfolio companies to discuss funding, the early-stage landscape for AI companies in healthcare, and what makes a successful strategic partnership. Register by July 23 to save on super early bird rates.

There are many exciting advancements in this dynamic sector of life sciences, and we hope you’ll join us in highlighting the latest innovations, as well as take advantage of the powerful partnering system that has made RESI events a mainstay in early-stage fundraising.

If you’d like to be considered to join a RESI AI panel, please apply here.

The RESI AI panels will focus on the following topics:

Healthcare Communications

Bridging the Gaps between Patient and Provider

Communication between patients and providers is essential to health systems globally. AI-enabled technology addressing these needs and creating innovative solutions help patients better access and comprehend their options and care. Hear from early-stage founders connecting the healthcare system one relationship at a time.

Accelerated Pharmaceutical Development

Advancing and Optimizing Clinical Processes

AI is a necessary component of many aspects of the development of pharmaceuticals. However, the COVID-19 global pandemic has highlighted the need for rapid and reliable pharmaceutical advancement. Learn how researchers can utilize AI to optimize performance and save lives.

Reproductive Wellness

Highlighting Innovation and Broad Applications

Comprehensive reproductive care has a global impact on health and society. AI-assisted advancement in this field is critical to provide access to patients regardless of location, medical history, and socioeconomic status. Hear from leaders how their technology is creating equity in quality and excellence in care.

Diagnostic Wearables

Connecting Patients to Their Health

Wearable sensors are a fast-growing area of medical device and diagnostic technology. The function and accuracy of these devices are critical to patient care and communication. AI is a powerful tool equipping these to provide accurate results up to the moment and enabling users to make well-informed decisions on their health.

Healthcare Systems and Infrastructure

Creating Synergy for Efficient Patient Care

Optimized healthcare systems and digital infrastructure are paramount to the patient experience. From electronic health records to portal access and communications, AI-enabled medical centers are better equipped to help patients in the digital age. When it comes to healthcare, small synergistic changes create a big impact on the patient experience and contribute to better systems globally.

Precision Medicine

Fitting the AI Piece of the Puzzle

The AI impact on precision medicine is essential in targeting and treating genetic disorders, rare diseases, oncology, and more. It’s important that entrepreneurs learn how to navigate pitfalls such as market saturation, regulatory risk and guidelines, as well as how to better define patient populations, challenges and tackle manufacturing and commercialization.

A Match Made at RESI: Part I

20 May

By Rory McCann, Marketing Manager & Conference Producer, LSN

Michele Marzola is a prolific investor and entrepreneur in healthcare with a career that spans decades. He knows exceptional technology when he sees it and a powerful team when he meets them, so when he met Antoine Prestat, founder of PEP-Therapy at RESI March 2020, he knew he’d found something special.

In Part I of our two-part interview about Michele’s investment in PEP-Therapy, we discuss his process when sourcing assets, due diligence, digital partnering, and his best advice to fundraising entrepreneurs.

There’s still time to sign up for Digital RESI June! Register today to start booking meetings with over 350 investors.  

Hot Investor Mandate: Private Wealth Firm Opportunistic Within Life Science Sectors, Investing As Early as Discovery/Pre-Prototype Stage of Development

20 May

A private wealth investment firm provides strategic and operational support for the firm’s investment initiatives and entrepreneurial endeavors. The firm invests in early to late stage (seed to pre-IPO) companies worldwide.

The firm is agnostic across life science sectors, including platforms, therapeutics, devices and tools, and services and including discovery, early stage preclinical and clinical-stage opportunities, though open to commercial-stage or adjacent discovery/development technologies.

The firm seeks companies with founders who have a clear vision, highly differentiated technology, and desire to build a durable business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →